Remove 2019 Remove Safety Remove Treatments
article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36
article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

article thumbnail

FDA Approves Galderma’s IL-31 Blocker in PN

The Dermatology Digest

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S.